{"id":3119,"date":"2016-03-01T06:35:46","date_gmt":"2016-03-01T06:35:46","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=5924"},"modified":"2016-03-01T06:35:46","modified_gmt":"2016-03-01T06:35:46","slug":"medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-notified-of-dea-clearance-for-import-of-high-purity-pharmaceutical-grade-cannabidiol-cbd","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/03\/01\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-notified-of-dea-clearance-for-import-of-high-purity-pharmaceutical-grade-cannabidiol-cbd\/","title":{"rendered":"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Notified of DEA Clearance for Import of High-Purity, Pharmaceutical-Grade Cannabidiol (CBD)"},"content":{"rendered":"
SAN DIEGO, March 01, 2016 (GLOBE NEWSWIRE) \u2014 Medical Marijuana, Inc.<\/a> (OTC Pink:MJNA) is pleased to announce that the Company\u2019s portfolio investment company, Kannalife Sciences, Inc. (\u201cKannalife\u201d), was recently informed that it has received the necessary 2016 quota allotment from the U.S. Drug Enforcement Administration (\u201cDEA\u201d) to import high-purity, pharmaceutical-grade cannabidiol into the U.S.<\/p>\n Kannalife, a Phyto-Medical Company, also announced new details and progress on its feasibility study being performed by Catalent Pharma Solutions (\u201cCatalent\u201d). The focus of the feasibility study with Catalent is to develop a drug product formulation with suitable solubility and stability for Investigational New Drug application (\u201cIND\u201d) enabling pre-clinical studies in animals and clinical studies in humans. As part of Kannalife\u2019s efforts to develop a cannabinoid-derived therapeutic agent for the treatment of two neurodegenerative diseases, hepatic encephalopathy (\u201cHE\u201d) and chronic traumatic encephalopathy (\u201cCTE\u201d), the feasibility study with Catalent will pave the way for the additional pre-clinical studies needed before the company files its IND with the U.S. Food and Drug Administration (\u201cFDA\u201d).<\/p>\n \u201cKannalife is making impressive strides forward in their research for a potential cannabinoid-based treatment for hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE). We applaud their entire team for their hard work and dedication in their efforts to bring novel cannabinoid-based therapies into the life sciences arena. Catalent is a proven global leader in bringing the highest-quality pharmaceutical products to market and we are excited for what\u2019s to come,\u201d states Dr. Stuart W. Titus, Chief Executive Officer of Medical Marijuana, Inc.<\/p>\n Kannalife currently holds two licenses from the National Institutes of Health for U.S. Patent 6,630,507 \u201cCannabinoids as Antioxidants and Neuroprotectants.\u201d These licenses are currently in use by Kannalife to develop proprietary therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE):\u00a0http:\/\/www.google.com\/patents\/US6630507<\/a>.<\/p>\n About Kannalife Sciences, Inc.<\/em><\/strong><\/p>\n Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (\u201cHE\u201d) and Chronic Traumatic Encephalopathy (\u201cCTE\u201d). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, please visit the company\u2019s website at:\u00a0www.Kannalife.com<\/a>.<\/p>\n About Medical Marijuana Inc.<\/em><\/strong>
\n
\n<\/em><\/strong>The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier cannabis and hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company\u2019s website at:<\/p>\n